Sionna Therapeutics, Inc.
SION · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.43 | -1.09 | -1.72 | 0.46 |
| FCF Yield | -1.17% | -2.37% | -3.55% | -1.07% |
| EV / EBITDA | -62.73 | -40.95 | -20.18 | -59.84 |
| Quality | ||||
| ROIC | -7.20% | -6.34% | -5.44% | -10.28% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 1.00 | 0.99 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 15.62% | -10.86% | -38.67% | 33.24% |
| Safety | ||||
| Net Debt / EBITDA | 2.07 | 1.77 | 3.81 | 1.56 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,332.90 | -559.59 | 0.00 | 0.00 |